A new clinical practice guideline from the American Academy of Sleep Medicine provides evidence-based recommendations on combining behavioral-psychological and pharmacological therapies for chronic insomnia disorder in adults. The guideline, published in the Journal of Clinical Sleep Medicine, offers insights into the combined use of these treatments, addressing a gap in previous guidelines that did not evaluate the comparative efficacy of combination therapy. The AASM suggests that Cognitive Behavioral Therapy for Insomnia (CBT-I) is the most effective first-line treatment, but combining it with medication may offer modest benefits for specific sleep outcomes. This recommendation emphasizes shared decision-making, considering patient values and preferences. The guideline was developed through a systematic review, meta-analysis, and evaluation of combination therapy's benefits and harms, with input from sleep medicine experts and public comment. It was affirmed by several medical associations and endorsed by various sleep-related organizations. The authors, including Dr. Daniel J. Buysse, highlight the importance of patient-centered decision-making in insomnia treatment, while also noting the potential risks associated with pharmacotherapy. The guideline provides valuable insights for healthcare professionals managing chronic insomnia, promoting informed and personalized treatment approaches.
